Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

全泽复 - NMPA Drug Approval Details

Approvals/NMPA/Cefdinir Capsules

Approved

化学药品

Cefdinir Capsules

LTL PHARMA CO., LTD.🇨🇳 National Medical Products Administration

Approval Date: Jul 24, 2023
Approval ID: 8TELMBO2vaY
Company: LTL PHARMA CO., LTD.
Type: 化学药品

Approval Details

Approval Id: 8TELMBO2vaY
Approval Number: 国药准字HJ20160520
Generic Name: 头孢地尼胶囊
Generic Name En: Cefdinir Capsules
Trade Name: 全泽复
Drug Type: 化学药品
Dosage Form: 胶囊剂
Strength: 0.1g(按C₁₄H₁₃N₅O₅S₂计算)
Reg Date: 2023-07-24
Expired Date: 2028-07-23
Company Name: LTL PHARMA CO., LTD.
Company Detail Path: /organization/ltl-pharma-co-ltd

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 24, 2023

Approval ID

8TELMBO2vaY

Type

化学药品

Back to NMPA Approvals